Reported that approximately 700,000 deaths occur worldwide each year due to bacterial resistance (García-Castro et al., 2023;Zhang et al., 2024). According to the World Health Organization report in early 2017, a list of antibiotic-resistant microorganismswas published, and this list includes the Enterobacteriaceae family, which is one of those considered highly pathogenic (Lamut etal., 2019; Zhang et al., 2024). Antibiotic resistance occurs after a complex process involving multiple mechanisms, and the efflux pump is only one of these mechanisms (Laws et al., 2022; Zhang et al., 2024). The RND efflux pump is also a mechanism from thesuperfamily class (Altinöz & Altuner, 2019; 2022; Altinoz et al., 2024). The RND efflux pump is an AcrAB-TolC complex proteincontaining AcrA, AcrB and TolC protein (Du et al., 2014; Szal et al., 2023; Altinoz et al., 2024). Efflux pump inhibitors can inactivatedrug transport or can be used to restore the effectiveness of resistant antibiotics (Mahey et al., 2021; Zhang et al., 2024). However,their clinical use is not yet suitable due to toxicity (Duffey et al., 2024). In this study, the potential inhibitory property of the hexacontane (67.34%) component in the methanol extract of the macrofungus Fomes fomentarius against the AcrB protein (RND efflux pump) was investigated by molecular docking method, the binding relationship between the protein and ligand and in silico study and ADMET analysis.
Methods
According to the data obtained from GC/MS analysis, it was seen that the methanol extract of Fomes fomentarius contained 67.34% hexacontane component. Molecular docking application for this component was performed with Autodock 1.5.6 program. 3D crystal structure of the component was downloaded from protein database in .pdb format. 1OYE, 1T9U, 1T9X, 1T9V, 1T9Y, 2W1B, 3W9H and 4DX5 close monomers from AcrB protein structure belonging to MDR E. coli bacteria were downloaded from protein database and processed. Hexacontane component was downloaded from PubChem in .sdf format and converted to .pdb in Open Babel GUI program. Water and ligand residues were removed from the proteins to be used and molecular docking process was applied. Protein-ligand conformation of the obtained analysis results was created in Biovia Discovery Studio program.
Results
Fomes fomentarius methanol extract contains 67.34% hexacontane component. Although it is the major component, it does not provide the expected binding energy in molecular docking analysis. The binding energies of the component to total of 8 proteins are, from low to high, respectively: 4DX5: +0.07 kcal/mol-1, 1T9X: +1.89 kcal/mol-1, 3W9H: +2.80 kcal/mol-1, 1T9U: +2.85 kcal/mol-1, 2W1B: +3.10 kcal/mol-1, 1OYE: +3.12 kcal/mol-1, 1T9V: +3.26 kcal/mol-1, 1T9Y: +4.56 kcal/mol-1 According to in silico ADMET results: There is no drug similarity according to Lipinski, Ghose, Veber, Egan and Muegge. Absorption properties; there is human intestinal absorption and Caco-2 permeability. Distribution; it passes the blood-brain barrier penetration but cannot provide renal organic cation transport. Organ toxicity; acute oral toxicity classification III and herG inhibition is weak. There is no genomic toxicity AMES toxicity but it has a harmful effect in terms of carcinogenicity.
Conclusions
The presence of Hexacontane component in a high ratio (67.34%) in the methanol extract of Fomes fomentarius in a major ratio clearly suggested that there would be protein-ligand compatibility. However, when the molecular docking analysis results were examined, it was seen that the opposite was true. Thus, it was observed that the major component in high proportions did not exhibit proper binding because they did not have the desired level of binding energy as a result of molecular docking analysis. According to the ADMET analysis, it was understood that the desired level of compliance was not achieved.. This shows that although there was a major component in the extract, the component was insufficient to be a potential efflux pump inhibitor according to molecular docking analysis.
Acknowledgment
The authors would like to thank the Kastamonu University Scientific Research Projects Coordination Department under the Grant No. KÜ-BAP01/2021-47 for the support.
García-Castro, M., Sarabia, F., Díaz-Morilla, A., & López-Romero, J. M. (2023). Approved antibacterial drugs in the last 10 years: From the bench to the clinic. Exploratory Drug Science, 1, 180–209.
Zhang, L., Tian, X., Sun, L., Mi, K., Wang, R., Gong, F., & Huang, L. (2024). Bacterial efflux pump inhibitors reduce antibiotic resistance. Pharmaceutics, 16, 170.
Lamut, A., Peterlin Mašić, L., Kikelj, D., & Tomašić, T. (2019). Efflux pump inhibitors of clinically relevant multidrug resistant bacteria. Medicinal Research Reviews, 39, 2460–2504.
Laws, M., Jin, P., & Rahman, K. M. (2022). Efflux pumps in Mycobacterium tuberculosis and their inhibition to tackle antimicrobial resistance. Trends in Microbiology, 30, 57–68.
Altinöz, E., & Altuner, E. M. (2019). Antibiotic resistance and efflux pumps. International Journal of Innovative Research and Reviews (INJIRR), 3(2), 1–9. file/995486
Altinöz, E., & Altuner, E. M. (2022). Observing the presence of efflux pump activities in some clinically isolated bacterial strains. International Journal of Biology and Chemistry, 15(1), 48–54.
Altinöz, E., Akata, E., & Altuner, E. M. (2024). Molecular docking application for the potential use of palmitic acid as an AcrB, an efflux pump protein, inhibitor. In Horizons of Innovation: Conference on Multidisciplinary Trends in Science 2024 (pp. 352-356). Futurity Research Publishing.
Du, D., Wang, Z., James, N. R., Voss, J. E., Klimont, E., Ohene-Agyei, T., ... & Luisi, B. F. (2014). Structure of the AcrAB-TolC multidrug efflux pump. Nature, 509(7501), 512–515.
Szal, T., Chauhan, S. S., Lewe, P., Rachad, F., Madre, M., Paunina, L., ... & Windshügel, B. (2023). Efflux pump-binding 4 (3-aminocyclobutyl) pyrimidin-2-amines are colloidal aggregators. Biomolecules, 13(6), Article 1000.
Mahey, N., Tambat, R., Chandal, N., Verma, D. K., Thakur, K. G., & Nandanwar, H. (2021). Repurposing approved drugs as fluoroquinolone potentiators to overcome efflux pump resistance in Staphylococcus aureus. Microbiology Spectrum, 9, e0095121.
Duffey, M., Jumde, R. P., da Costa, R. M., Ropponen, H. K., Blasco, B., & Piddock, L. J. (2024). Extending the potency and lifespan of antibiotics: Inhibitors of gram-negative bacterial efflux pumps. ACS Infectious Diseases, 10(5), 1458-1482.
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2012). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews, 64, 4–17.
Lee, S. K., Chang, G. S., Lee, I. H., Chung, J. E., & Sung, K. Y. (2004). The PreADME: PC-based program for batch prediction of ADME properties. EuroQSAR, 9, 5–10.
Yang, H., Lou, C., Sun, L., Li, J., Cai, Y., Wang, Z., & others. (2019). AdmetSAR 2.0: Web-service for prediction and optimization of chemical ADMET properties. Bioinformatics, 35, 1067–1069.